Vir Biotechnology Inc.

Vir Biotechnology Inc. is a clinical-stage biopharmaceutical company that discovers, develops, and advances immune-based therapies to treat and prevent serious infectious diseases and cancer. The company leverages its next-generation antibody platform and PRO-XTEN protease-releasable masking technology to power the immune system against unmet medical needs. Its lead program features the combination of tobevibart, a broadly neutralizing monoclonal antibody, and elebsiran, a siRNA targeting hepatitis B virus, in Phase 3 trials through the ECLIPSE registrational program for chronic hepatitis delta virus. In oncology, Vir Biotechnology advances PRO-XTEN dual-masked T-cell engagers, including VIR-5500 targeting PSMA for metastatic castration-resistant prostate cancer, VIR-5818 for HER2-expressing tumors, and VIR-5525 for EGFR-expressing solid tumors, all in Phase 1 development. Preclinical efforts target influenza, RSV, human metapneumovirus, HPV, HIV, and other indications. Founded in 2016 and headquartered in San Francisco, California, Vir Biotechnology focuses on immunology-driven innovation across infectious diseases and oncology to deliver potentially transformative medicines.